Expanded Access Protocol With ABT-888 (Veliparib) in Patients With Metastatic BRCA-Mutation Associated or Triple Negative Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02985658

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:38:05.753109+00:00

Published At

2021-07-21T00:00:00+00:00

Record Updated At

2021-07-21

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation", "Triple-Negative Breast Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2021-07-21"

protocolSection.identificationModule.nctId

"NCT02985658"

protocolSection.identificationModule.officialTitle

"Expanded Access Protocol With ABT-888 (Veliparib) in Patients With Metastatic BRCA-Mutation Associated or Triple Negative Breast Cancer"

protocolSection.statusModule.overallStatus

"NO_LONGER_AVAILABLE"

protocolSection.designModule.phases

[]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation (protocolSection.conditionsModule.conditions)
• Triple-Negative Breast Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.